HYDERABAD, June 24: Indian Immunologicals Ltd
(IIL), a city-based biologicals company, Monday announced the
ground-breaking of a new Sterile Filling Facility (SFF) at its
manufacturing plant in Phase III of Genome Valley, in Ranga
Reddy district, with an investment of Rs 75 crore.
According to a press release issued by IIL, with this
upcoming filling facility, the company expects to increase its
capacity to supply lifesaving vaccines such as the Anti Rabies
Vaccine (ARV) Abhayrab.
The new state-of-the-art facility expected to be ready
later next year.
The sterile filling facility is equipped with hi-end
equipment from the world’s best manufacturers, in line with
the requirements of the nature of work handled at the plant,
it said.
K Anand Kumar, Managing Director of IIL said the
animal health and human health player has a long history of
supplying vaccines critical to public health.
“We are constantly striving to make the vaccines
affordable and accessible to reach the benefits of preventive
healthcare to maximum number of people. The expansion at
Karkapatla plant is in line with our mission and will help
meet the growing requirements of critical vaccines,” he said.
IIL has four manufacturing facilities at various
locations Karkapatla, Telangana Human Vaccines and Animal
Health Formulations; Udhagamadalam, Tamil Nadu Anti Rabies
production unit; Hyderabad, Telangana Human Biologicals Unit
(Gachibowli) and animal vaccines unit; Dargaville, New Zealand
– New Bovine Serum. (PTI)
Follow our WhatsApp channel